Multimodal intervention approach shows promise in managing and reversing cognitive impairment

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

Ver­tex said it made $2 mil­lion in rev­enue from the first pa­tient who re­ceived its sick­le cell ther­a­py Cas­gevy. The com­mer­cial launch­es of Cas­gevy and